The companies Kailera Therapeutics, Summit Therapeutics, and Tubulis bagged the biggest biotech funding rounds overall in October 2025.

Pichia pastoris is emerging as a versatile, efficient alternative for protein production, bridging microbial and mammalian expression systems.

From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.

The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

Discover eight key AI biotech deals that have been made so far in 2025, spotlighting where industry leaders are betting big.

After decades of research, gut microbiome therapies are beginning to reach the market. Here are 11 of the companies harnessing the power of the microbiome to develop treatments derived from the gut.

Asking whether China is the future of the biotech industry might seem counterintuitive, considering the current biotech geopolitical context. If you haven’t followed this series of events, a ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to the loss of muscle control. As motor neurons ...

Last year, we took a look at the biotech trends that we thought would shape 2024. Now, as we enter the new year, the biotech industry is continuing to evolve at a rapid pace, and 2025 is shaping up to ...

Unlike other industries, biotech startups often require substantial initial capital to support extensive research and development (R&D), clinical trials, and regulatory approvals before generating any ...

Dive into this whitepaper and learn about: The limitations of current hybridoma and single B cell screening techniques Why traditional discovery workflows are inefficient and prone to overlooking ...